Abeona Therapeutics Inc. (NASDAQ:ABEO) Stock Has Consensus Target Price of $21.00Defense World · Oct 16, 2026
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEOGlobeNewsWire · Oct 6, 2026
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire · Oct 2, 2026
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEOPRNewsWire · Oct 1, 2026
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEOGlobeNewsWire · Sep 29, 2026
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEOPRNewsWire · Sep 24, 2026Abeona Therapeutics Inc. is a biopharmaceutical company in the clinical development stage, focused on creating innovative gene and cell therapies to address severe and uncommon genetic diseases. Its leading program, EB-101, an autologous gene-corrected cell therapy, is presently in a Phase III clinical trial for treating recessive dystrophic epidermolysis bullosa. The company's pipeline also features several other promising therapies: ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 13, 2026 | -$0.23 | -$0.35 | Miss |
| May 13, 2026 | -$0.33 | -$0.30 | Beat |
| Mar 17, 2026 | -$0.35 | -$0.34 | Beat |
| Nov 12, 2025 | -$0.27 | -$0.10 | Beat |
| Aug 11, 2025 | -$0.39 | $1.71 | Beat |
| May 14, 2025 | -$0.35 | -$0.24 | Beat |